{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.4","upperLimit":"31.4","value":"15.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"TTP is defined as the time from the date of the first dose of study treatment to the date of the first documented disease progression or relapse","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.","reportingStatus":"POSTED","timeFrame":"duration of study up to approx. 4 years","title":"Time to Progression/Relapse (TTP) Per Investigator","type":"SECONDARY","unitOfMeasure":"months"}